

SATELLITE SYMPOSIA I – V

S U N D A Y - March 16, 2025

16.45-17.45 SATELLITE SYMPOSIUM I (SAT I)

Industry sponsored Satellite (**Daiichi Sankyo**)

Lecture Hall III (Overflow Rooms: LHs IV+V)

AML Unpacked: Awareness, Management and Latest Trends in Fit Newly Diagnosed Patients

Meeting Objectives:

- Review the current treatment landscape for fit patients with newly diagnosed FLT3-mutated AML
- Discuss the assessment of fit patients with newly diagnosed AML, looking to novel targets on the horizon

16.45-16:50

Welcome and Introduction

L. Bullinger, Berlin, DE

16:50-17.10

K. Döhner, Ulm, DE. *State of the Art: Treatment Landscape for Fit Patients with Newly Diagnosed FLT3-Mutated AML*

17:10-17:30

P. Vyas, Oxford. UK. *Hot Topics: Assessing Fit Patients with Newly Diagnosed AML – Novel Targets on the Horizon*

17:30-17.45

Panel Discussion and Closing - All Faculty

M O N D A Y - March 17, 2025

16:30-17:30: SATELLITE SYMPOSIUM II (SAT II)

Industry sponsored Session (**Otsuka Pharma GmbH**)

Lecture Hall III (Overflow Rooms: LHs IV/V)

Managing Difficult Decisions in Unfit AML Patients in the Context of the New ELN 2024 Recommendations

16.30-16.50

L. Bullinger, Berlin, DE. *Current and Future Treatment Options for Unfit AML Patients*

16:50-17.05

E. Jost, Aachen, DE: *How to Treat ELN 2024 Intermediate/Adverse-Risk Patients: Combination Therapy Beats HMA Monotherapy?*

17:05-17:25

W. Kirakosow, Mühlheim a.d.R., DE: *How to Treat ELN 2024 Intermediate/Adverse-Risk Patients: Still Room for HMA Monotherapy?*

17:25-17.30

Closing Remarks

18:00-19:00: SATELLITE SYMPOSIUM III (SAT III)

Industry sponsored Satellite (**AbbVie Deutschland GmbH**)

Lecture Hall III (Overflow Rooms: LHs IV/V)

Exploring Future Treatment Strategies for AML Patients

18:00-18:05

Welcome and Introduction/Chair:

L. Bullinger, Berlin, DE

18:05-18.25

Ch. Röllig, Dresden, DE: *Treatment of IC-Ineligible AML Patients – How Can Novel Strategies Improve Clinical Results?*

18:25-18:45

Ch. Craddock, Birmingham, UK: *Reaching New Heights: Advancing Outcomes for Transplant Patients in AML*

18:45-18.55

Panel Discussion and Q&A

All Faculty

18:55-19.00

Closing Remarks

L. Bullinger, Berlin, DE

T U E S D A Y - March 18, 2025

16:15-17:15: SATELLITE SYMPOSIUM IV (SAT IV)

Industry sponsored Satellite (**Servier France**)

Lecture Hall III (Overflow Rooms LHs IV+V)

Targeting IDH1 Mutations in Front Line AML for the Unfit Patient

16:15-16:20

Gail Roboz, New York, NY, USA: *Emerging Induction Strategies in AML*

16:20-16:30

Hartmut Doehner, Ulm, DE: *Exploring Therapeutic Strategies for IDH1-Mutated Patients*

16:30-16:40

Maria Teresa Voso, Rome, I: *Molecular Testing- When and How?*

16:40-16:50

Lars Fransecky, Kiel, DE: *Clinical Case Presentation*

16:50-17:00

Michael Kuehn, Mainz, DE: *Shaping the Future of AML Care: Clinical Trials for Targeted Therapies*

17:00-17:15

Questions and Discussion

All Faculty

17.45-18.45: SATELLITE SYMPOSIUM V (SAT V)

Industry sponsored Session (**Amgen GmbH**)

Lecture Hall III (Overflow Rooms LHs IV+V)

A New Era: Immunotherapy for Newly Diagnosed B-ALL

17:45-17:50

Welcome and Introduction

M. Subklewe, Munich, DE

17:50-18.15

N. Gökbuget, Frankfurt, DE: *Immunotherapy in Frontline Treatment of Ph-negative and -positive B-ALL*

18:15-18:40

M. Subklewe, Munich, DE: *The Future: SC Application and New Indications*

18:40-18.45

Closing Remarks

N. Gökbuget, Frankfurt, DE